|
Click Here To
Unsubscribe
|
Members,
We've discovered a 1-cent growth company that develops biological detection and diagnostic systems for America's homeland defense and the global healthcare industry.
Historically they have worked with large government and commercial partners such as the Department of Homeland Security (DHS) to develop and manufacture its products and have received up to $30 million in contract funding.
Our new trade continues to work with DHS and is also currently working the Department of Defense (DOD), NASA, U.S. Special Operations Command, and well as several high profile government contractors.
It also has an exclusive license and a teaming agreement with The Boeing Company, wherein Boeing was granted the exclusive right to distribute M-BAND units in North America, and PositiveID became the exclusive provider of reagents and assays to Boeing.
The company's M-BAND detection system currently being deployed to customers and its revolutionary new Firefly Dx product expected to hit the market sometime in 2015, it would be foolish to not expect it to have its best year yet.
We believe this new alert is set to makes its next move higher, and it could be by far the biggest move in the history of this exciting biological detection and diagnostic system company.
Members,
Monday and Tuesday's alerts were duds...
Previous to this disappointing duo, we brought subscribers 8 winners in a row that produced a combined total of more than +776% in profit.
We plan to return to our winning ways tomorrow with a low-priced, bottom-chart biotechnology company poised for triple-digit percent gains!
Immediately turn your attention to PSID (PositiveID Corp.).
PSID is an emerging growth company that develops biological detection and diagnostic systems for America's homeland defense and the global healthcare industry.
It is focused primarily on its M-BAND airborne bio-threat detector, which was developed under contract with the U.S. Department of Homeland Security ("DHS") Science & Technology directorate, and its Firefly Dx system, which is designed to deliver molecular diagnostic results from a sample in less than 30 minutes at the point-of-need, using a portable, handheld system.
These devices use real-time polymerase chain reaction (PCR) chemistry. PCR amplifies a sample’s DNA and copies it billions of times. PCR is used every day to diagnose diseases, identify bacteria and viruses, and for many other applications. With real-time PCR, the amplification of the DNA can be measured as it occurs, thereby speeding up the ability to deliver results. Real-time PCR is one of the most sensitive and specific bio-detection capabilities available today.
PSID's M-BAND detection system continuously and autonomously analyzes air samples for the detection of pathogenic bacteria, viruses, and toxins for up to 30 days. Results from individual M-BAND instruments are reported via a secure wireless network in real time to give an accurate and up-to-date status of field conditions. M-BAND performs high specificity detection for up to six organisms on the Centers for Disease Control's category A and B select agents list.
The goal of PSID's Firefly Dx is provide real-time, accurate diagnostic results in a handheld device, thereby leading to treatment scenarios at the point of need that are not possible with existing systems, which require lab-based equipment and can take hours or even days to provide results. The system has already demonstrated the ability to detect and identify other common pathogens and diseases such as various strains of influenza, E. coli, methicillin-resistant staphylococcus aureus ("MRSA") and human papilloma virus ("HPV").
PSID historically has worked with large government and commercial partners such as the Department of Homeland Security (DHS) to develop and manufacture its products. The company’s M-BAND product was developed with $30 million of contract funding under the DHS’ BAND program.
The company continues to work with DHS and is also currently working the Department of Defense, NASA, U.S. Special Operations Command, and well as several high profile government contractors.
PSID has an exclusive license and a teaming agreement with The Boeing Company, wherein Boeing was granted the exclusive right to distribute M-BAND units in North America, and PositiveID became the exclusive provider of reagents and assays to Boeing.
PSID announced that it has made significant progress in the first quarter of 2015 with its Firefly Dx system last week.
The company's first quarter of 2015 highlights include:
- Completed the design of the second-phase (bench-top) prototype of Firefly Dx, the first major milestone in the development of the second-phase prototype.
- Commenced building the second-phase prototype of Firefly Dx.
- Prepared additional M-BAND systems for field deployment and testing
- Issued revenue guidance of $3-6 million for 2015.
- Completed the build of its Firefly Dx polymerase chain reaction (PCR) chip, and started testing assays to prove the design of achieving PCR results in less than 20 minutes.
- Filed a new U.S. patent for Firefly Dx: "A Cyclical and Continuous Flow PCR Device," which covers a cyclical mechanism of thermal cycling required to complete real-time PCR and deliver results in less than 20 minutes.
- Filed an additional U.S. patent for Firefly Dx: "A Cyclical PCR Device with Reusable Heat Zones".
- Completed additional testing of its phase II Firefly Dx, and detected multiple organisms with a multiplex assay designed to simultaneously test for up to four pathogens on the PCR chip.
The company reported almost $1 million in revenue for the year ending December 31, 2014.
PSID continues to align itself for success...
William J. Caragol, Chairman and CEO of PSID stated "As we continue to advance the development and testing of Firefly Dx, which is being built to capitalize on a multi-billion dollar market opportunity and unmet requirement for point-of-need, real-time PCR testing, we are excited with our progress to date and the opportunity to deliver a system that could revolutionize the way biological samples are tested, while delivering significant value to our stockholders."
The global PCR industry is projected to reach $27.4 billion in 2015 on positive growth prospects of PCR equipments and reagents segment.
With PSID's M-BAND detection system currently being deployed to customers and its revolutionary new Firefly Dx product expected to hit the market sometime in 2015, it would be foolish to not expect the company to have its best year yet.
PSID is currently trading at the low end of its 52-week price channel at just $0.0181 per share.
PSID has recently established a double bottom support level coupled with large volume spikes. Why is this so important? The increased volume confirms the support level is strong and hints towards a possible reversal hence leading to a breakout. You can also see a very clear and concise downtrend resistance line in place. As that downtrend line approaches the support level, an inflection point is created. One of those lines have to give. Either support wins or resistance wins. And in this case, the increased volume on the creation of a double bottom support hints towards a complete reversal and momentum building breakout.
PSID is no stranger to momentum-based breakouts...
Just a few months ago, PSID erupted for a strong multi-day gain of +143.33%!
We believe that PSID is set to makes its next move higher, and it could be by far the biggest move in the history of this exciting biological detection and diagnostic system company.
We are urging all of our members to continue their research on PSID tonight, and be ready for an exciting and potentially profitable trading day that kicks off tomorrow at 9:30am EST!
For more information on PSID, please visit their website: www.PSIDCorp.com
Best Regards,
The ResearchOTC Team
|
|
Disclaimer:
This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated and edited by MJ Capital, LLC. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” or “MJ Capital” refers to MJ Capital, LLC. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature, and are therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions, and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website.
We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here.
MJ Capital’s business model is to receive financial compensation to promote public companies. We have been compensated eleven thousand dollars cash via bank wire by a third party, Hanover Financial Services, LLC, to conduct investor relations advertising and marketing for PSID. Any compensation is a major conflict of interest in our ability to be unbiased. Any compensation is a major conflict of interest in our ability to be unbiased. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forword looking statements, which are not guaranteed to materialize due to a variety of factors.
We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, MJ Capital often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.
|
Best Regards,
The ResearchOTC Team
|
|
|
|
|
